View Clinical trials for Veldoreotide Get Veldoreotide Patent Info for Free

COR-005 (veldoreotide) is an investigational somatostatin analogue (SSA) in development for treatment of patients with acromegaly. SSAs bind to somatostatin receptors, inhibiting secretion of growth hormone. It is beleived that COR-005 may offer an improved safety and efficacy profile—compared with current SSAs—because of its differentiated activation of somatostatin receptor subtypes. COR-005 has received orphan drug designation for acromegaly in the US and EU. COR-005 (veldoreotide) is currently being optimized for sustained release and subcutaneous delivery.

Inn NameVeldoreotide
Usan NameVeldoreotide
Lab CodesCOR-005, DG-3173, PTR-3173
Chemical NameGlycinamide, N-(4-amino-1-oxobutyl)-L-phenylalanyl-L-tryptophyl-D-tryptophyl-L-lysyl-L-threonyl-L-phenylalanyl-N2-(3-carboxypropyl)-, (7→1)-lactam
Alternate NameSomatoprim
Somatostatin analog
Chemical StructureVeldoreotide.png
Molecular FormulaC60H74N12O10
Cas Registry Number252845-37-7
Orphan Drug StatusYes
Orphan IndicationAcromegaly
New Molecular EntityYes
DeveloperCortendo AB, Strongbridge Biopharma plc, Aspireo Pharmaceuticals Limited
Mechanism Of ActionSomatostatin receptor 2, 4 and 5 agonist.

Free counters!